糖尿病诺和灵30R治疗者更换诺和锐30后疗效观察

Clinical efficacy of BIAsp30 instead of BHI30 in diabetic patients

目的观察使用诺和灵30R治疗的糖尿病患者更换成诺和锐30治疗后的疗效观察。方法使用胰岛素诺和灵30R治疗而血糖仍未达标的糖尿病患者48例,随机分成两组,治疗组和对照组各24例。治疗组将诺和灵30R更换成诺和锐30治疗,对照组继续使用诺和灵30R治疗。两组均根据血糖调整胰岛素剂量,如果胰岛素用量达到30U,则联用口服降糖药物二甲双胍或阿卡波糖治疗。观察两周,比较两组血糖控制情况;胰岛素使用剂量;口服降糖药使用情况;低血糖发生情况。结果两组治疗后血糖控制均优于治疗前;治疗组餐后血糖控制优于对照组;两组胰岛素使用剂量无明显差异;两组口服降糖药物使用率无明显差异;两组低血糖发生率无明显差异。结论使用诺和锐30治疗餐后血糖控制更满意,胰岛素联用口服降糖药物较单独使用胰岛素疗效更佳。

Objective To observe the effect of BIAsp30 instead of BHI30 in diabetic patients. Methods 48 patients with type2 diabetes mellitus who were treated with BHI30 had unsatisfiedly controlled blood glucose. They were randomly divided into two groups： treatment group and the control group, with 24 patients in each group. The treatment group was administered with BIAsp30. The control group was still treated with BHI30. The dosage of insulin were adjusted by the blood glucose supervise in two groups. If the dosage of insulin was above 30u, then combined with oral antidiabetic agents such as metformin and acarbose. After two weeks of the continuous therapy, the two groups were compared with the standard of the blood glucose, the dosage of insulin, the use of the oral antidiabetic agents and the occurrence of the glycopenia. Results The two groups had satisfied blood glucose then before. The treatment group had better clinical efficacy than the control group of the postprandial blood glucose. The dosage of insulin, the use of the oral antidiabetic agents and the occurrence of the glycopenia of two groups had no significance difference. Conclusion BIAsp30 can improve clinical efficacy of the postprandial blood glucose in patients with diabetes mellitus. Insulin combined with oral antidiabetic agents can improve clinical efficacy in patients with diabetes mellitus.